跳到正文
制药经理人· GxP知识岛·· 12 天前精选AI 评分82

FDA公布默沙东Merck Teknika达勒姆厂483检查报告并列出6项观察

FDA 483:默沙东 Merck Teknika公司(中英文对照)

AI 导读

FDA公布对默沙东旗下Merck Teknika位于北卡罗来纳州达勒姆的生物制品生产厂(FEI 1039284)的483检查报告,共列6项观察。观察称主要设备2023年6月9日的再确认已失败,质量审核至2024年11月8日才完成,期间设备持续用于生产。无菌工艺气流可视化试验未覆盖现场实际发生的人工干预,另有约9起关键缺陷偏差在纠正性维修与CAPA后仍持续发生。

推荐理由

六项观察涉及设备再确认失败后仍放行使用、无菌工艺烟雾试验未覆盖实际干预以及关键缺陷偏差反复发生,可供对照检查缺陷的表述方式。

正文

近日,FDA公布了对默沙东(Merck & Co.,美国、加拿大以外称MSD)旗下Merck Teknika公司位于北卡罗来纳州达勒姆的生物制品生产厂(100 Rodolphe St, Bldg 1300,FEI 1039284)的检查报告,签发6项观察。

6项观察里,最重的是两条:一是主要设备的再确认在2023年6月9日就已失败,设备却一直用到2024年11月8日质量部门才审完,中间17个月;二是无菌工艺的气流可视化(烟雾)试验,从未覆盖现场实际发生的人工干预。此外,同一类临界缺陷在两年多里累计9起偏差,纠正措施做完仍未止住。

以下为原文与中文对照,涂黑处按原件以(b)(4)标示,未作补写。

OBSERVATION 1

观察1

The responsibilities and procedures applicable to the quality control unit are not fully followed.

质量管理部门(QCU)应尽的职责与程序,未被完全遵守。

Specifically,

具体而言:

A. The review and approval process of the qualification of major equipment is deficient. Requalification of the (b)(4) used in (b)(4) Suite, Room (b)(4), performed in March 2023, failed, which led to the initiation of a significant investigation, QN 201091153, on 03May2023.

A. 主要设备确认的审核与批准流程存在缺陷。2023年3月对(b)(4)套间(b)(4)房间内所用(b)(4)进行的再确认失败,由此于2023年5月3日启动重大调查 QN 201091153。

The BCG Vaccine manufacturing process has two (2) Critical Process Parameters (CPP) associated with the (b)(4) and (b)(4). The (b)(4) is utilized to cool the (b)(4) prior to use during the (b)(4) Process.

卡介苗生产工艺有2个关键工艺参数(CPP)与(b)(4)和(b)(4)相关。(b)(4)用于在(b)(4)工序使用前冷却(b)(4)。

A repeat requalification was performed on 9Jun2023 using the protocol (b)(4). The associated investigation was closed on 15Jun2023, and equipment was released for manufacturing, without confirming that the generated data were within the acceptance criteria.

2023年6月9日按方案(b)(4)进行了再次再确认。相关调查于2023年6月15日关闭,设备被放行用于生产,而未确认所生成的数据是否落在接受标准之内。

Quality review and approval of the executed re-qualification protocol was completed only on 08Nov2024. During the review process, the firm identified that the execution performed on 9Jun2023 failed due to (b)(4) data points reported outside the acceptance criteria of the protocol. The delay in Quality review process led to utilize the equipment in its failed requalified state since 9Jun2023.

已执行的再确认方案直到2024年11月8日才完成质量审核与批准。审核过程中企业发现,2023年6月9日的执行因(b)(4)个数据点超出方案接受标准而不合格。质量审核的延误,导致该设备自2023年6月9日起一直在再确认不合格的状态下被使用。

B. Procedure SOP-6970/QC50.308, Data Invalidation Procedure (Version 7.0, Effective Date: JUL-11-2024) outlines steps required for identifying, assigning, and tracking invalid data generated by testing performed in the BCG (b)(4) laboratories. This procedure requires invalid data trending reports to be conducted on a (b)(4) basis. These reports require approval from QC Management and Quality. However, the reports REI-013935057, REI-014096931, REI-014354108, which covered the period JAN-01-2023 to DEC-31-2023, JAN-01-2024 to MAR-31-2024, and APR-01-2024 to JUN-30-2024 respectively, were approved by QC management only.

B. 程序 SOP-6970/QC50.308《数据作废程序》(第7.0版,生效日2024年7月11日)规定了在卡介苗(b)(4)实验室检验中所产生的无效数据的识别、指派与追踪步骤。该程序要求按(b)(4)周期编制无效数据趋势报告,且报告须经QC管理层与质量部门批准。但覆盖2023年1月1日至12月31日、2024年1月1日至3月31日、2024年4月1日至6月30日的三份报告 REI-013935057、REI-014096931、REI-014354108,仅经QC管理层批准。

OBSERVATION 2

观察2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

为防止声称无菌的药品受到微生物污染而设计的程序,未包含对无菌工艺的充分验证。

Specifically,

具体而言:

Airflow visualization studies (Smoke studies) were not performed for the following inherent and corrective interventions performed during the aseptic (b)(4) process of BCG Vaccine.

卡介苗无菌(b)(4)工序中下列固有干预与纠正性干预,均未开展气流可视化试验(烟雾试验)。

A. On 20Nov2024, during the fill line setup of BCG Vaccine batch (b)(4) using aseptic (b)(4), we observed a Grade (b)(4) operator using an empty tray for removing the entire vials from the vial (b)(4). A vial storage (b)(4) was accidentally slipped and fell over the vials. This intervention was never evaluated in the air flow visualization studies.

A. 2024年11月20日,在无菌(b)(4)条件下进行卡介苗批(b)(4)灌装线装料时,检查员看到一名(b)(4)级区操作员用空托盘将西林瓶从瓶(b)(4)中整盘取出;期间一个储瓶(b)(4)意外滑脱并压在西林瓶上。该干预从未在气流可视化试验中评价过。

B. The (b)(4) changeout is a corrective intervention during the (b)(4) process. This was never evaluated through smoke studies.

B. (b)(4)更换是(b)(4)工序中的一项纠正性干预,从未通过烟雾试验评价。

C. On 20Nov2024, during the (b)(4) set-up for BCG Vaccine batch (b)(4), the (b)(4) had alignment issues. The Grade (b)(4) operator entered inside the protective enclosure around the (b)(4) to complete the set-up process. This intervention was never evaluated in the air flow visualization studies. (b)(4) were present in the (b)(4) during this corrective intervention.

C. 2024年11月20日,卡介苗批(b)(4)进行(b)(4)装配时,(b)(4)出现对位问题。(b)(4)级区操作员进入(b)(4)外围的防护罩内以完成装配。该干预从未在气流可视化试验中评价过;此次纠正性干预期间,(b)(4)内存在(b)(4)。

OBSERVATION 3

观察3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

为防止声称无菌的药品受到微生物污染而设计的程序,未建立或未遵循。

Specifically, On 20Nov2024, during the (b)(4) process of BCG Vaccine batch (b)(4) using aseptic (b)(4), we observed the following:

具体而言:2024年11月20日,在无菌(b)(4)条件下进行卡介苗批(b)(4)的(b)(4)工序时,检查员观察到以下情形:

A. Grade (b)(4) Operators involved in (b)(4) assembly set-up and (b)(4) operation lacked deliberate (b)(4).

A. (b)(4)级区参与(b)(4)装配装料与(b)(4)操作的人员,缺乏有意的(b)(4)。

B. During adjustment of (b)(4), the Grade (b)(4) operator's arms and upper torso were observed reaching over the (b)(4).

B. 调节(b)(4)时,看到(b)(4)级区操作员的手臂与上臂越过(b)(4)上方。

C. (b)(4) used for troubleshooting the non-viable particulate (b)(4) alarms were not discarded after touching the (b)(4). The (b)(4) was placed near other (b)(4) which were utilized by Grade (b)(4) operators for opening the (b)(4) of (b)(4).

C. 用于排查悬浮粒子(b)(4)报警的(b)(4),在接触(b)(4)后未丢弃。(b)(4)被放置在其他(b)(4)附近,而那些(b)(4)是(b)(4)级区操作员用于开启(b)(4)的(b)(4)的。

D. (b)(4) inside the Grade (b)(4) operator's goggles was observed.

D. 看到(b)(4)级区操作员的护目镜内有(b)(4)。

OBSERVATION 4

观察4

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

对任何无法解释的差异,无论批次是否已经放行销售,均未进行彻底调查。

Specifically,

具体而言:

a. The firm has initiated about 9 deviation investigations pertaining to exceedance of (b)(4) (b)(4) defects (Critical defect). This is a critical defect with an action limit of NMT (b)(4) (NMT (b)(4) after January 2024). These deviations related to action level defects are still ongoing, despite corrective maintenance and CAPAs.

a. 企业就(b)(4)缺陷(关键缺陷)超标共启动约9起偏差调查。该缺陷为关键缺陷,行动限为不超过(b)(4)(2024年1月起为不超过(b)(4))。尽管已做纠正性维修并实施CAPA,这些与行动水平缺陷相关的偏差至今仍在发生。

通知号
Notification

日期
Date

根本原因 / Root Cause

201023681

25-Aug-22

(b)(4) misalignment: bulk of (b)(4) defects occurred prior to intervention to correct (b)(4)
(b)(4)对位不良:大部分(b)(4)缺陷发生在纠正(b)(4)的干预之前

201046528

2-Nov-22

(b)(4) misalignment during setup
装料过程中(b)(4)对位不良

201066792

30-Jan-23

(b)(4) sealing
(b)(4)密封不良

201142692
(AQL failure)

13-Nov-23

Missed defect during product inspection
产品检查时漏检缺陷

201140987

3-Nov-23

(b)(4) that is used to move vials was causing product in vials to (b)(4). (b)(4) was adjusted to slow it down.
用于传送西林瓶的(b)(4)导致瓶内产品(b)(4),已将(b)(4)调慢

201142875

3-Nov-23
10-Nov-23
21-Nov-23
7-Dec-23

(b)(4) malfunction: suspect (b)(4) were removed from process, the (b)(4) defect generation rate decreased significantly, indicating that the root cause of the (b)(4) defects was due to (b)(4) malfunction.
(b)(4)故障:将有嫌疑的(b)(4)撤出工序后,(b)(4)缺陷发生率显著下降,表明(b)(4)缺陷的根本原因是(b)(4)故障

201187804

30-May-24
6-Jun-24

(b)(4) alignment due to setup variability
因装料波动导致(b)(4)对位不良

201192046

19-Jun-24

(b)(4) alignment due to setup variability
因装料波动导致(b)(4)对位不良

201220844

4-Oct-24
18-Oct-24
13-Nov-24

Ongoing investigation
调查进行中

(注)表中“Batch”与“Product in (b)(4) defect %”两列在原件中整列被(b)(4)遮蔽,故未列出。/注:原表共6列,批次与缺陷率两列整列涂黑。

b. Deviation QN 201039748 (initiated 10/06/2022) for BCG Batch (b)(4) and QN 201189268 (initiated 06/09/2024) for BCG Batch (b)(4) were found out of specification (OOS). The BCG means for both batches were (b)(4) exceeding the release specification of (b)(4) per test method (b)(4) "Dry Weight Determination".

b. 卡介苗批(b)(4)的偏差 QN 201039748(2022年10月6日启动)与批(b)(4)的 QN 201189268(2024年6月9日启动)被判定为检验结果超标(OOS)。两批的卡介苗均值均为(b)(4),超出按检验方法(b)(4)《干重测定法》规定的放行标准(b)(4)。

According to (b)(4) Test Investigation Procedure for Out of Specification (OOS) and Atypical Results, a Data Validity Task (b)(4) should be created in (b)(4) as part of the (b)(4) analysis to determine whether the test is valid or invalid before conducting a retest. Despite this requirement, no data validity task was created in (b)(4); retests were performed on 01/30/2023 for Batch (b)(4) and on 08/26/2024 for Batch (b)(4). The initial test results generated on 10/06/2022 and 06/09/2024 were invalidated without quality approval prior to retesting.

按(b)(4)《OOS与非典型结果检验调查程序》,在复测之前应在(b)(4)中创建数据有效性任务(Data Validity Task),作为(b)(4)分析的一部分,以判定该检验有效或无效。尽管有此要求,企业未在(b)(4)中创建数据有效性任务;批(b)(4)于2023年1月30日、批(b)(4)于2024年8月26日直接进行了复测。2022年10月6日与2024年6月9日产生的初始检验结果,在未经质量批准的情况下即被作废。

Both BCG batches, (b)(4) and (b)(4), were subsequently released based on the retest results without properly determining the validity of the original test.

此后,两批卡介苗(b)(4)与(b)(4)均依据复测结果放行,而未对原始检验的有效性作出适当判定。

c. Your firm failed to initiate a deviation or exception report when the 2023 annual requalification, dated 09/25/2023 (b)(4) of the (b)(4), used to sterilize (b)(4) and (b)(4) etc.) failed acceptance criteria deeming the run invalid.

c. 2023年度再确认(日期2023年9月25日,即用于灭菌(b)(4)与(b)(4)等的(b)(4)之(b)(4))未达到接受标准、该次运行被判无效时,企业未启动偏差或例外报告。

A second run cycle was performed 11/15/2023 which resulted in failure to meet acceptance criteria. The firm initiated a work order, WO 53653773, to inspect the door (b)(4) and it was observed that the (b)(4) (b)(4) door (b)(4) was replaced. A (b)(4) requalification run cycle was performed on 01/18/2024, which resulted in a failure to meet acceptance criteria.

2023年11月15日进行第二次运行,仍未达到接受标准。企业开具工单 WO 53653773 检查(b)(4)门,发现(b)(4)的(b)(4)门(b)(4)已更换。2024年1月18日又进行了一次(b)(4)再确认运行,仍未达到接受标准。

The root cause was determined to be a malfunctioning (b)(4); however, the (b)(4) was determined functioning prior to use, according to the (b)(4) temperature report, dated 09/13/2023. A (b)(4) requalification run cycle was performed on 02/07/2024.

根本原因被判定为(b)(4)故障;但按2023年9月13日的(b)(4)温度报告,该(b)(4)在使用前被判定功能正常。2024年2月7日进行了一次(b)(4)再确认运行。

The firm's investigation initiated based on the (b)(4) run cycle failure did not include a risk assessment for the batches manufactured prior to the WO performed on 11/15/2023. There were (b)(4) of BCG batches manufactured and released using (b)(4) and (b)(4) sterilized in the (b)(4) from 09/25/2023-11/15/2023.

企业基于该(b)(4)运行失败所启动的调查,未对2023年11月15日工单执行之前所生产批次进行风险评估。2023年9月25日至11月15日期间,有(b)(4)批卡介苗使用在该(b)(4)中灭菌的(b)(4)与(b)(4)生产并放行。

OBSERVATION 5

观察5

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

用于药品生产、加工、包装或贮存的设备,其设计不足以支持按预期用途进行操作。

Specifically, The (b)(4) used in (b)(4) Suite, Room (b)(4) is utilized to (b)(4) the (b)(4) for (b)(4). The firm's requalification performed in 9Jun2023 using the protocol (b)(4) was designed to study the criteria for (b)(4) while in production, the time allowed is a (b)(4). The requalification strategy is not designed for the (b)(4) to ensure that the (b)(4) are cooled to (b)(4) of (b)(4). The firm manufactures about (b)(4) BCG vaccine batches (b)(4) utilizing this equipment.

具体而言:(b)(4)套间(b)(4)房间内所用的(b)(4),用于为(b)(4)而(b)(4)该(b)(4)。企业2023年6月9日按方案(b)(4)实施的再确认,设计目的是研究生产状态下(b)(4)的判定标准,所允许的时间为(b)(4)。该再确认策略并非针对(b)(4)设计,无法确保(b)(4)被冷却至(b)(4)的(b)(4)。企业利用该设备生产约(b)(4)批卡介苗(b)(4)。

OBSERVATION 6

观察6

Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

设备与器具未按规定间隔维护,以防止可能改变药品安全性、鉴别、含量、质量或纯度的污染。

Specifically, From 03/31 to 04/07/2023, during annual requalification of the (b)(4) ((b)(4)), the equipment underwent maintenance to replace and (b)(4) (b)(4) used during production. However, (b)(4) (b)(4) remained in service throughout this period. Sterilized components from the (b)(4) were used in the manufacture and release of (b)(4) BCG batches for distribution.

具体而言:2023年3月31日至4月7日,在(b)(4)((b)(4))的年度再确认期间,设备进行了维护,更换生产中所用的(b)(4)与(b)(4)。但(b)(4)的(b)(4)在整个期间仍继续使用。来自该(b)(4)的已灭菌部件,被用于(b)(4)批卡介苗的生产与放行销售。

来源:制药经理人 · mp.weixin.qq.com

所属事件

查看事件全部
FDA公布默沙东达勒姆BCG厂六项483观察